Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

On October 20, 2025, scientists announced a significant advancement toward curing HIV, marking a pivotal moment in the ongoing battle against the virus. This breakthrough builds on a series of ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Gear-obsessed editors choose every product we review. We may earn commission if you buy from a link. Why Trust Us? Here's what you'll learn when reading this story: The challenge with curing the Human ...

Formed in 1976 by vocalist Robert Smith and drummer Lol Tolhurst, the Cure offered a refreshing antidote to the hyper-masculine rock stars of the ’80s. Despite selling more than 30 million records ...

The Cure's Robert Smith in June 2023 (photo: Adam Bettcher / Getty Images). It took the Cure 16 years to release a studio album after 2008’s 4:13 Dream, but it seems that Robert Smith and company are ...

Merck (NYSE:MRK) reported positive results from late-stage studies on a new oral treatment which combines two drugs, doravirine and islatravir, for adults with HIV-1. The studies looked at adults ...

ViiV Healthcare, a healthcare company founded by Pfizer (NYSE:PFE) and GSK (NYSE:GSK), announced on Wednesday that its long-acting HIV PrEP therapy cabotegravir was found to be more acceptable to ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV ...